- Company
- ‘Various treatment options emerged for ulcerative colitis'
- by Son, Hyung Min Dec 6, 2024 05:57am
- “Various treatment options such as biologics and JAK inhibitors have emerged for ulcerative colitis, but the patients’ options are limited because the government does not allow switching between drugs. Especially as the number of young patients in their 20s and 30s and their life expectancy is both increasing, securing various treatment op
- Company
- Roche's new PNH drug 'Piasky' expected to be launched in KOR
- by Eo, Yun-Ho Dec 6, 2024 05:56am
- A new PNH drug, 'Piasky,' is expected to be launched in South Korea. According to industry sources, Roche Korea is currently undergoing the approval review process for Piasky (crovalimab), a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). This drug received the U.S. Food and Drug Administration (FDA) approval in June. In Augus
- Company
- GC Biopharma will distribute and sell Fluad Quad in Korea
- by Kim, Jin-Gu Dec 5, 2024 05:53am
- GC Biopharma will distribute and sell CSL Seqirus’s quadrivalent flu vaccine, ‘Fluad Quad Prefilled Syringe (Fluad Quad),’ in Korea. According to industry sources on the 3rd, GC Biopharma recently signed a contract with Meditip to distribute and sell Fluad Quad in Korea. Meditip holds the domestic rights to the main product of the A
- Company
- Sales of new CAR-T drugs Carvykti 88%↑· Kymriah stalled
- by Son, Hyung Min Dec 5, 2024 05:53am
- Sales performance of Chimeric Antigen Receptor (CAR)-T Cell therapies has been interchanging. Novartis' Kymriah, which entered the market first, is troubling as latecomer competitors enter the market. In contrast, sales of Jansen's Carvykti and BMS' Breyanzi expanded significantly due to expanded indications. According to the pharmaceutical i
- Company
- Biosimilars Onbevezy·Remsima compete for sales lead in KOR
- by Chon, Seung-Hyun Dec 5, 2024 05:53am
- Biosimilars developed by Celltrion and Samsung Bioepis have been expanding their presence in the domestic market. Samsung Bioepis' Onbevezy has surpassed sales of KRW 10 billion, becoming the top-selling biosimilar developed in South Korea. Since Q3 of last year, Celltrion's Remsima has allowed Onbevezy to take a market-leading position. However
- Company
- Boryung starts in-house producing lung cancer drug 'Alimta'
- by Heo, sung-kyu Dec 4, 2024 05:56am
- As Boryung has started in-house production of 'Alimta (pemetrexed),' a non-small cell lung cancer (NSCLC) treatment that Boryung acquired the sales right in 2022, attention is drawn to the background. Analysis indicates that Boryung aims to take a share of the market worth KRW 20 billion as part of a synergistic strategy for operating a manuf
- Company
- SK Bioscience wins 2nd trial on pneumococcal patent dispute
- by Kim, Jin-Gu Dec 4, 2024 05:56am
- &160; SK Bioscience has won the second trial of its patent infringement lawsuit against Pfizer over its pneumococcal vaccine, overturning the ruling made in the first trial.&160; The two companies have been engaged in a long-running lawsuit over SK Bioscience's 13-valent pneumococcal vaccine, ‘Skypheumo Prefilled Syringe (Skypheumo).’
- Company
- Sanofi announces entering the RSV vacc. market for children
- by Whang, byung-woo Dec 4, 2024 05:56am
- Sanofi has announced the launch of Beyfortus, an injectable antibody drug to prevent respiratory syncytial virus (RSV) lower respiratory tract disease, for the first time in South Korea. The company aims to take a market share. As clinical practices are in high demand for the vaccine, proactive RSV prevention will become possible following th
- Company
- GSK seeks HIV paradigm shift with long-acting injectable
- by Whang, byung-woo Dec 4, 2024 05:56am
- With the long-acting HIV drug Vocabria+Rekambys combination therapy seeking insurance reimbursement coverage, attention is being paid to whether the drug’s introduction will bring about a shift in the treatment environment. According to industry sources on the 3rd, GSK Korea has completed pharmacoeconomic evaluations for its new HIV dru
- Company
- 4 out of 5 pharmas saw export sales expanded
- by Kim, Jin-Gu Dec 3, 2024 05:53am
- Export sales of four out of five pharmaceutical and biotech companies have increased year-over-year (YoY). The net export sales of 28 major pharmaceutical companies increased from KRW 5.3405 trillion to KRW 6.6449 trillion over a year, up 25.6%. Samsung Biologics' export sales increased by over KRW 600 billion. Export sales of Celltrion
